Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States

References

• Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136-46
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80
   PubMed Web of Science ®Google Scholar
• About irritable bowel syndrome (IBS). International Foundation for Functional Gastroinestinal Disorders (IFFGD), 2010. www.aboutibs.org/#rates. Accessed February 15, 2013
   Google Scholar
• Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004;20:339-45
   PubMed Web of Science ®Google Scholar
• Longstreth G. Rome III diagnostic criteria: functional constipation and IBS-C. Gastroenterology 2006; http://ww3.peerviewpress.com/gpimgs/fastcast/n165/pdf/table2.pdf. Accessed May 3, 2011
   Google Scholar
• Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(1 Suppl):S1-35
   PubMedGoogle Scholar
• Guerin A, Carson R, Kaminsky M, et al. Medical costs associated with treatment failure with over-the-counter or prescription constipation treatments in patients with IBS-C in a Medicaid population. J Manag Care Pharm 2013;19:179
   Google Scholar
• Dibonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011;27:2213-22
   PubMed Web of Science ®Google Scholar
• Ironwood Pharmaceuticals I. LINZESS (linaclotide) Prescribing Information. United States Food and Drug Administration, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202811s000lbl.pdf. Accessed June 17, 2013
   Google Scholar
• Center for Drug Evaluation and Research. Medical review: Lubiprostone for the treatment of irritable bowel syndrome with constipation (Application 21-908s005). United States Food and Drug Administration, 2008
   Google Scholar
• Vieira MC, Ellis A, Lembo T, et al. Randomized controlled trials of treatments for irritable bowel syndrome with constipation and chronic constipation: evaluation of measurement and reporting of efficacy and identification of evidence gaps. Presented at the ACG Annual Scientific Meeting: October 19-24 2012 Las Vegas, NV, 2012
   Google Scholar
• Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-24
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration CfDEaR. Guidance for industry: Irritable Bowel Syndrome - Clinical evaluation of drugs for treatment. U.S Department of Health and Human Services, 2012
   Google Scholar
• Drossman D, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007;102:1442-53
   PubMed Web of Science ®Google Scholar
• Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400-11
   PubMed Web of Science ®Google Scholar
• Red Book Online: Lubiprostone WAC Price. Thomson Reuters, 2012. Accessed August 31, 2012
   Google Scholar
• Red Book Online: LINZESS (linaclotide) WAC Price. Truven Health Analytics 2013. Accessed March 22, 2013
   Google Scholar
• Menzin J, Huang H, Carson RT, et al. Assessment of practice patterns and treatment-failure costs among patients with irritable bowel syndrome with constipation: findings from a physician survey study. Presented at the ISPOR 15th Annual European Congress, 3–7 November 2012, Berlin, Germany, 2012
   Google Scholar
• Huang H, Taylor D, Carson RT, et al. Impact of treatment response on health utilities and work productivity among patients with irritable bowel syndrome with constipation: pooled results from Phase III Clinical Trials. Presented at the ISPOR 15th Annual European Congress, 3–7 November 2012, Berlin, Germany, 2012
   Google Scholar
• Bureau of Labor Statistics. May 2010 National occupational employment and wage estimates United States. United States Department of Labor, 2011. http://www.bls.gov/oes/current/oes_nat.htm#00-0000. Accessed March 6, 2012
   Google Scholar
• Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-12
   PubMed Web of Science ®Google Scholar
• Miller ME, Zuckerman S, Gates M. How do Medicare physician fees compare with private payers? Health Care Financ Rev 1993;14:25-39
   PubMedGoogle Scholar
• Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar